The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD . Actualité en allergologie et en immunologie au Canada, Toronto, Canada, v. 2, n. s11, p. 3–11, 2022. DOI: 10.58931/cait.2022.2s1148. Disponível em: https://canadianallergyandimmunologytoday.com/article/view/2-s11-lacuesta_and_lee. Acesso em: 20 mars. 2026.